Note 1 - Nature of Business and Significant Accounting Policies (Details) |
9 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|
|
Dec. 10, 2014
shares
|
Nov. 12, 2014
shares
|
Feb. 28, 2017
USD ($)
|
Feb. 29, 2016
USD ($)
|
May 31, 2015
USD ($)
|
May 31, 2016
USD ($)
|
|
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] | ||||||
| Stockholders' Equity, Reverse Stock Split | 1-for-0.625 | |||||
| Stockholders' Equity Note, Stock Split, Conversion Ratio | 0.625 | |||||
| Stock Issued During Period, Value, New Issues | $ 15,000,000 | |||||
| Cash and Cash Equivalents, at Carrying Value | $ 5,940 | $ 30,170 | $ 208,821 | $ 88,244 | ||
| Advertising Expense | 0 | 9 | ||||
| Research and Development Expense | $ 0 | $ 9 | ||||
| Shares of CLS Holdings USA, Inc. [Member] | CLS Labs, Inc. [Member] | ||||||
| Note 1 - Nature of Business and Significant Accounting Policies (Details) [Line Items] | ||||||
| Subsidiary or Equity Method Investee, Cumulative Number of Shares Issued for All Transactions (in Shares) | shares | 6,250,000 | 10,000,000 | ||||
| Equity Method Investment, Ownership Percentage | 55.60% | |||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Cumulative number of shares issued or sold by the subsidiary or equity method investee on all stock transactions. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|